Patients diagnosed with tumor stage III or IV NSCLC can undergo treatment with PD-1 blockade (2), and can have response rates of up to 30–45% within 9–18 months, with a durable response (>2 years) in some patients (3). Here, PDCD1 is linked to neoplasm.